本研究调查了5-氟尿嘧啶加载的氧化锌纳米复合材料（5-FU/Gd-ZnO NCs）作为潜在的癌症治疗方法。5-氟尿嘧啶是一种常用的抗癌药物，但副作用不可忽视。采用了PXRD、FTIR、FESEM、TEM、DLS、电位和AFM等多种技术对材料进行了表征。数据表明，纳米复合材料呈现出片状团聚，颗粒直径范围从317.6nm到120.1nm不等。发现抑制细胞生长的5-氟尿嘧啶-氧化锌纳米复合物（5-FU-ZnO）的IC50值为1.85ppm。还研究了5-FU-ZnO对炎症标志物的影响。5-氟尿嘧啶增加了TNF-α和IL-1β的水平，而纳米复合材料能够降低这些水平。此外，5-FU/Gd-ZnO-NCs组显示出硫醇水平上升和过氧化氢酶及超氧化物歧化酶水平下降的情况。流式细胞术结果显示，5-氟尿嘧啶、氧化锌纳米复合材料和5-FU/Gd-ZnO-NCs对抑制或清除癌细胞没有任何加成或协同效应。体内实验显示，与自由药物相比，5-FU/Gd-ZnO NCs具有相似的坏死特征，并减少了纤维化和胶原沉积。与5-FU组相比，纳米复合材料还表现出更高的抗氧化活性和较低的炎症反应。证明了5-FU/Gd-ZnO-NCs成功抑制了细胞增殖。体内实验的结果与自由5-FU获得的结果相当，表明这些纳米复合材料具有作为治疗用药的潜力。© 2023. 作者，独家授权给斯普林格-费尔拉格德国有限公司，斯普林格自然出版集团部分。

The study investigated the use of 5-fluorouracil-loaded ZnO nanocomposites (5-FU/Gd-ZnO NCs) as a potential treatment for cancer. 5-FU is a commonly used drug for cancer treatment but has undesirable side effects. The materials were characterized using various techniques, including PXRD, FTIR, FESEM, TEM, DLS, £-potential, and AFM. The data showed that the nanocomposites had a plate-like agglomeration with particle diameters ranging from 317.6 to 120.1 nm. The IC50 value of 5-FU-ZnO, which inhibits cell growth, was found to be 1.85 ppm. The effects of 5-FU-ZnO on inflammatory markers were also examined. While 5-FU increased the levels of TNF-a and IL-1b, the nanocomposites were able to reduce these levels. Additionally, the 5-FU/Gd-ZnO-NCs group showed an increase in thiol levels and a decrease in catalase and superoxide dismutase levels. Flow cytometry results showed that 5-FU, ZnO-NCs, and 5-FU/Gd-ZnO-NCs did not have any additive or synergistic effects on the suppression or eradication of cancer cells. In vivo, experiments showed that the 5-FU/Gd-ZnO NCs had similar necrotic characteristics and reduced fibrosis and collagen deposition compared to the free medication. The nanocomposites also exhibited higher antioxidative activity and lower inflammatory responses compared to the 5-FU group. It was shown that 5-FU/Gd-ZnO-NCs successfully inhibit cell proliferation. The in vivo results were comparable to those obtained with free 5-FU, suggesting the potential of these nanocomposites as therapeutic agents.© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.